Vitamins
Minerals
Fitness Nutrition
Omega & Fish Oil
Nutritional Drinks
Digestive Care
Diabetic Care
Bone & Joints Care
Respiratory Care
Women Care
Skin Care
Ear Nose Throat
Sexual Wellness
Liver Care
Immunity Boosters
Skin Care
Oral Care
Hair Care
Men Grooming
Baby Food
Baby Hair Care
Baby Skin Care
Baby Bath Care
Diapers
Feminine Hygiene
Women Grooming
Women Nutrition
Blood Glucose
Blood Pressure
Support & Braces
Health Vitals
Test Kits
Nebulizers
Oral Contraceptives
Condoms
Pleasure Enhancers
Protective Gear
Personal & Home
Remogliflozin etabonate is a medication that contains the active ingredient remogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor.It is available in tablet form.
Remogliflozin etabonate is indicated for the treatment of type 2 diabetes mellitus in adults to improve glycemic control.
It is typically used in combination with other diabetes medications, such as metformin or insulin.
Sgltr Tab (Remogliflozin Etabonate) works by blocking the SGLT2 protein in the kidneys, which prevents the reabsorption of glucose back into the bloodstream. This results in increased glucose excretion in the urine, lowering blood sugar levels.
Store remogliflozin etabonate tablets at room temperature, between 20°C and 25°C (68°F and 77°F). Protect from moisture and light.
The recommended starting dose of remogliflozin etabonate is 100 mg once daily.
Your doctor may adjust your dosage based on your individual needs and response to treatment.
Take remogliflozin etabonate with a meal, once daily.
Do not crush, break, or chew the tablets. Swallow them whole.
Common side effects include urinary tract infections, vaginal yeast infections, and increased urination.
More serious side effects can occur, such as dehydration, low blood sugar (hypoglycemia), and ketoacidosis (a serious complication of diabetes).
Alcohol consumption can increase the risk of hypoglycemia, especially in patients taking insulin or other medications that can lower blood sugar.
Remogliflozin etabonate may cause dizziness or lightheadedness. Avoid driving or operating machinery until you know how this medication affects you.
Remogliflozin etabonate is not recommended for use during pregnancy. It is also not known if the medication is safe for use during breastfeeding.
Remogliflozin etabonate is not approved for use in children.
Remogliflozin etabonate is eliminated primarily by the kidneys. It may need to be used with caution in patients with kidney disease.
Remogliflozin etabonate does not appear to be significantly affected by liver function. It can be used in patients with liver disease.
The prescribing information for remogliflozin etabonate.
The website of the Food and Drug Administration (FDA).
